Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 159,500 shares, a decrease of 71.2% from the January 31st total of 553,500 shares. Based on an average daily trading volume, of 454,300 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.5% of the company’s stock are sold short.

Alterity Therapeutics Stock Up 2.4 %

ATHE stock opened at $3.96 on Friday. The business has a 50 day moving average of $3.74 and a 200-day moving average of $2.21. Alterity Therapeutics has a 12-month low of $1.00 and a 12-month high of $5.87.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. HB Wealth Management LLC raised its stake in shares of Alterity Therapeutics by 34.1% during the 4th quarter. HB Wealth Management LLC now owns 31,883 shares of the company’s stock worth $110,000 after purchasing an additional 8,100 shares during the period. BNP Paribas Financial Markets bought a new position in Alterity Therapeutics during the fourth quarter valued at about $29,000. Finally, Point72 Asset Management L.P. purchased a new stake in Alterity Therapeutics during the fourth quarter worth about $108,000. Institutional investors own 2.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on ATHE shares. Benchmark cut Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a research note on Monday, February 3rd. Maxim Group raised their price target on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, January 30th.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.